Imaging scan that targets PD-L1 in digestive cancer
Part of Cancer, Digestive system clinical trials.
This study tests an imaging method that looks for PD-L1 (a protein linked to some cancers) in solid tumors, including gastrointestinal cancers. It may help doctors better see where PD-L1 is in the body using a scan.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are over 18 years old.
- Your health status is fairly good (ECOG 0–1).
- You have a gastrointestinal (digestive) cancer.
- A scan shows at least one measurable tumor spot.
- You are expected to live at least 12 more weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special injectable imaging agent (a 'probe') that lights up a protein called PD-L1 on your tumor cells. It helps doctors see your tumors more clearly on a PET scan, which may guide treatment decisions.
This trial tests a new type of imaging scan that uses a special tracer to help doctors see solid tumors more clearly. The scan may help improve how tumors are detected and monitored during treatment.
This trial uses a special PET scan to take pictures of certain solid tumors. The scan uses a new dye that may help doctors see the tumors more clearly. You may be eligible if you have one of the listed cancers and are between 18 and 75 years old with good daily function.
This trial tests a special imaging agent (a nanobody probe) that targets a protein called CD147 on tumor cells. If you have a solid tumor like melanoma, liver, colorectal, pancreatic, breast, stomach, or lung cancer, the PET scan may help doctors see your cancer more clearly.
This trial tests a special injection (a radioactive tracer) that lights up PD-L1 in your tumors during a PET scan. It helps doctors see which tumors might respond to immunotherapy.
This trial tests a new type of imaging scan (PD-L1 PET/CT) that may help doctors better see and understand cancers. The scan uses a special tracer to highlight cancer cells in your body, which could help guide treatment decisions.
Hear when a new Gastrointestinal Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.